KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Research & Development (2016 - 2025)

Historic Research & Development for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $13.5 million.

  • Emergent BioSolutions' Research & Development fell 217.39% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year decrease of 4483.52%. This contributed to the annual value of $70.7 million for FY2024, which is 3653.5% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Research & Development stood at $13.5 million, which was down 217.39% from $12.5 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Research & Development high stood at $52.5 million for Q1 2021, and its period low was $9.1 million during Q4 2024.
  • Moreover, its 5-year median value for Research & Development was $32.7 million (2024), whereas its average is $31.5 million.
  • Examining YoY changes over the last 5 years, Emergent BioSolutions' Research & Development showed a top increase of 2576.92% in 2024 and a maximum decrease of 6904.76% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Research & Development (Quarter) stood at $38.2 million in 2021, then rose by 23.04% to $47.0 million in 2022, then tumbled by 37.45% to $29.4 million in 2023, then crashed by 69.05% to $9.1 million in 2024, then surged by 48.35% to $13.5 million in 2025.
  • Its Research & Development was $13.5 million in Q3 2025, compared to $12.5 million in Q2 2025 and $15.1 million in Q1 2025.